Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
Lancet (London, England)
|
December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV
|
May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
Ian Frank, Shuying S Li, Nicole Grunenberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy
Sara E Looby, Amy Kantor, Tricia H Burdo, et al.
JACC. Advances
|
June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations
Julia Karady, Michael T Lu, Göran Bergström, et al.
JAMA Cardiology
|
February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial
Michael T Lu, Heather Ribaudo, Borek Foldyna, et al.
The New England Journal of Medicine
|
July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Steven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Giuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.
The New England Journal of Medicine
|
December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Katharine J Bar, Michael C Sneller, Linda J Harrison, et al.
The New England Journal of Medicine
|
August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
Lancet (London, England)
|
December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV
|
May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
Ian Frank, Shuying S Li, Nicole Grunenberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy
Sara E Looby, Amy Kantor, Tricia H Burdo, et al.
JACC. Advances
|
June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations
Julia Karady, Michael T Lu, Göran Bergström, et al.
JAMA Cardiology
|
February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial
Michael T Lu, Heather Ribaudo, Borek Foldyna, et al.
The New England Journal of Medicine
|
July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Steven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Giuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.
The New England Journal of Medicine
|
December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Katharine J Bar, Michael C Sneller, Linda J Harrison, et al.
The New England Journal of Medicine
|
August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Page
of 10